Serveur d'exploration sur l'opéra

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

OP0224 A placebo-controlled phase II study of hyperimmune caprine serum as potential treatment for established diffuse cutaneous systemic sclerosis

Identifieur interne : 000636 ( Main/Exploration ); précédent : 000635; suivant : 000637

OP0224 A placebo-controlled phase II study of hyperimmune caprine serum as potential treatment for established diffuse cutaneous systemic sclerosis

Auteurs : N. Quillinan [Royaume-Uni] ; D. Mcintosh [Royaume-Uni] ; S. Haq [Royaume-Uni] ; C. Denton [Royaume-Uni]

Source :

RBID : ISTEX:2C6A6FB30DD0B4AF084C4EFB9761DEDD51AEC43B

Abstract

Objectives Hyperimmune caprine (goat) serum prepared under GMP conditions has been used to treat a number of inflammatory or autoimmune diseases including chronic inflammatory demyelinating polyneuropathy. We have performed a study to explore safety and tolerability of hyperimmune caprine serum (AIMSPRO®) in established diffuse cutaneous systemic sclerosis (dcSSc). Potential measures of efficacy and markers of biological activity were also examined. Methods A double blind parallel group placebo controlled clinical trial was performed under clinical trial authorisation from the UK MHRA and with institutional ethical approval. After informed consent 20 patients with established dcSSc of greater than 3 years duration were randomised to receive either active (n=10) or placebo formulation (n=10) by subcutaneous twice weekly injection over 26 weeks. Safety and tolerability were assessed by AE and SAE monitoring. Clinical endpoints (MRSS, HAQ-DI and SF-36) were compared between baseline and 26 weeks. Clinically meaningful change in MRSS was defined as greater than 4 skin score units and more than 20% change from baseline. Serum levels of vWF, PIIINP and sIL-2R were measured to assess vascular, fibrotic and immunological pathology. Exploratory serum biomarkers were also measured including MCP-1 (CCL-2) that has previously been associated with clinical severity in SSc. Results There were no safety concerns during this study. Frequency of adverse events was not different between active and placebo treated patients; 154 AE occurred in those receiving placebo and 139 AE in the AIMSPRO® treated subjects. The commonest adverse event was minor injection site reaction occurring in 12 subjects. There were 6 SAE in 3 subjects in the placebo group and 4 SAE in 3 subjects receiving active treatment. No SAE was judged treatment-related. Mean (±SD) baseline MRSS for the trial cohort was 15.1±7.1, with no significant difference between active or placebo groups. Mean skin score fell by 1.4±4.7 units with active treatment but worsened by 2.1±6.4 units on placebo. This difference did not reach statistical significance (p=0.18, unpaired t-test). Responder analysis suggested clinically meaningful improvement in MRSS at 26 weeks occurred in 5 (50%) of actively treated patients compared with 1 (10%) in the control group. 2 subjects showed deterioration of MRSS in each treatment group. Mean±SD for HAQ-DI at baseline was 1.15±0.07 for active and 1.59±0.63 for placebo group and at 26 weeks was 1.24±0.98 for active and 1.56±0.55 for placebo. These changes were not statistically different (p=0.34). No other clinical endpoints changed significantly in either treatment group. There were no significant changes in vWF, sIL-2R or PIIINP but serum levels of MCP-1 (pg/ml) showed a reduction after AIMSPRO® (baseline 262.3±101.1, 202.4±132.0 at 26 weeks) compared with placebo (baseline 280.6±133.6, 325.8±225.9 at 26 weeks) with a trend of difference between cohorts (p=0.10, unpaired t-test). Conclusions These results confirm the tolerability and safety of this novel biological agent in a complex multisystem autoimmune rheumatic disease. Although not powered to confirm efficacy, the improvement in MRSS observed in half of subjects receiving active treatment cases warrants further evaluation. Disclosure of Interest N. Quillinan: None Declared, D. McIntosh Shareholder of: Daval International Ltd., Consultant for: Daval International Ltd., S. Haq Shareholder of: Daval International Ltd., C. Denton: None Declared

Url:
DOI: 10.1136/annrheumdis-2012-eular.1907


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">OP0224 A placebo-controlled phase II study of hyperimmune caprine serum as potential treatment for established diffuse cutaneous systemic sclerosis</title>
<author>
<name sortKey="Quillinan, N" sort="Quillinan, N" uniqKey="Quillinan N" first="N." last="Quillinan">N. Quillinan</name>
</author>
<author>
<name sortKey="Mcintosh, D" sort="Mcintosh, D" uniqKey="Mcintosh D" first="D." last="Mcintosh">D. Mcintosh</name>
</author>
<author>
<name sortKey="Haq, S" sort="Haq, S" uniqKey="Haq S" first="S." last="Haq">S. Haq</name>
</author>
<author>
<name sortKey="Denton, C" sort="Denton, C" uniqKey="Denton C" first="C." last="Denton">C. Denton</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:2C6A6FB30DD0B4AF084C4EFB9761DEDD51AEC43B</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1136/annrheumdis-2012-eular.1907</idno>
<idno type="url">https://api.istex.fr/document/2C6A6FB30DD0B4AF084C4EFB9761DEDD51AEC43B/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001371</idno>
<idno type="wicri:Area/Istex/Curation">001371</idno>
<idno type="wicri:Area/Istex/Checkpoint">000016</idno>
<idno type="wicri:doubleKey">0003-4967:2013:Quillinan N:op:a:placebo</idno>
<idno type="wicri:Area/Main/Merge">000629</idno>
<idno type="wicri:Area/Main/Curation">000636</idno>
<idno type="wicri:Area/Main/Exploration">000636</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">OP0224 A placebo-controlled phase II study of hyperimmune caprine serum as potential treatment for established diffuse cutaneous systemic sclerosis</title>
<author>
<name sortKey="Quillinan, N" sort="Quillinan, N" uniqKey="Quillinan N" first="N." last="Quillinan">N. Quillinan</name>
<affiliation wicri:level="3">
<country>Royaume-Uni</country>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<wicri:orgArea>Centre for Rheumatology, UCL Medical School, Royal Free Campus, Rowland Hill Street</wicri:orgArea>
</affiliation>
</author>
<author>
<name sortKey="Mcintosh, D" sort="Mcintosh, D" uniqKey="Mcintosh D" first="D." last="Mcintosh">D. Mcintosh</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Daval International Ltd., Eastbourne, East Sussex, Bn21 4Rl</wicri:regionArea>
<wicri:noRegion>Bn21 4Rl</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Haq, S" sort="Haq, S" uniqKey="Haq S" first="S." last="Haq">S. Haq</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Daval International Ltd., Eastbourne, East Sussex, Bn21 4Rl</wicri:regionArea>
<wicri:noRegion>Bn21 4Rl</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Denton, C" sort="Denton, C" uniqKey="Denton C" first="C." last="Denton">C. Denton</name>
<affiliation wicri:level="3">
<country>Royaume-Uni</country>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<wicri:orgArea>Centre for Rheumatology, UCL Medical School, Royal Free Campus, Rowland Hill Street</wicri:orgArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Annals of the Rheumatic Diseases</title>
<title level="j" type="abbrev">Ann Rheum Dis</title>
<idno type="ISSN">0003-4967</idno>
<idno type="eISSN">1468-2060</idno>
<imprint>
<publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<date type="published" when="2013-06">2013-06</date>
<biblScope unit="volume">71</biblScope>
<biblScope unit="issue">Suppl 3</biblScope>
<biblScope unit="page" from="131">131</biblScope>
</imprint>
<idno type="ISSN">0003-4967</idno>
</series>
<idno type="istex">2C6A6FB30DD0B4AF084C4EFB9761DEDD51AEC43B</idno>
<idno type="DOI">10.1136/annrheumdis-2012-eular.1907</idno>
<idno type="href">annrheumdis-71-131-2.pdf</idno>
<idno type="ArticleID">annrheumdis-2012-eular.1907</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0003-4967</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass></textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">Objectives Hyperimmune caprine (goat) serum prepared under GMP conditions has been used to treat a number of inflammatory or autoimmune diseases including chronic inflammatory demyelinating polyneuropathy. We have performed a study to explore safety and tolerability of hyperimmune caprine serum (AIMSPRO®) in established diffuse cutaneous systemic sclerosis (dcSSc). Potential measures of efficacy and markers of biological activity were also examined. Methods A double blind parallel group placebo controlled clinical trial was performed under clinical trial authorisation from the UK MHRA and with institutional ethical approval. After informed consent 20 patients with established dcSSc of greater than 3 years duration were randomised to receive either active (n=10) or placebo formulation (n=10) by subcutaneous twice weekly injection over 26 weeks. Safety and tolerability were assessed by AE and SAE monitoring. Clinical endpoints (MRSS, HAQ-DI and SF-36) were compared between baseline and 26 weeks. Clinically meaningful change in MRSS was defined as greater than 4 skin score units and more than 20% change from baseline. Serum levels of vWF, PIIINP and sIL-2R were measured to assess vascular, fibrotic and immunological pathology. Exploratory serum biomarkers were also measured including MCP-1 (CCL-2) that has previously been associated with clinical severity in SSc. Results There were no safety concerns during this study. Frequency of adverse events was not different between active and placebo treated patients; 154 AE occurred in those receiving placebo and 139 AE in the AIMSPRO® treated subjects. The commonest adverse event was minor injection site reaction occurring in 12 subjects. There were 6 SAE in 3 subjects in the placebo group and 4 SAE in 3 subjects receiving active treatment. No SAE was judged treatment-related. Mean (±SD) baseline MRSS for the trial cohort was 15.1±7.1, with no significant difference between active or placebo groups. Mean skin score fell by 1.4±4.7 units with active treatment but worsened by 2.1±6.4 units on placebo. This difference did not reach statistical significance (p=0.18, unpaired t-test). Responder analysis suggested clinically meaningful improvement in MRSS at 26 weeks occurred in 5 (50%) of actively treated patients compared with 1 (10%) in the control group. 2 subjects showed deterioration of MRSS in each treatment group. Mean±SD for HAQ-DI at baseline was 1.15±0.07 for active and 1.59±0.63 for placebo group and at 26 weeks was 1.24±0.98 for active and 1.56±0.55 for placebo. These changes were not statistically different (p=0.34). No other clinical endpoints changed significantly in either treatment group. There were no significant changes in vWF, sIL-2R or PIIINP but serum levels of MCP-1 (pg/ml) showed a reduction after AIMSPRO® (baseline 262.3±101.1, 202.4±132.0 at 26 weeks) compared with placebo (baseline 280.6±133.6, 325.8±225.9 at 26 weeks) with a trend of difference between cohorts (p=0.10, unpaired t-test). Conclusions These results confirm the tolerability and safety of this novel biological agent in a complex multisystem autoimmune rheumatic disease. Although not powered to confirm efficacy, the improvement in MRSS observed in half of subjects receiving active treatment cases warrants further evaluation. Disclosure of Interest N. Quillinan: None Declared, D. McIntosh Shareholder of: Daval International Ltd., Consultant for: Daval International Ltd., S. Haq Shareholder of: Daval International Ltd., C. Denton: None Declared</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Royaume-Uni</li>
</country>
<region>
<li>Angleterre</li>
<li>Grand Londres</li>
</region>
<settlement>
<li>Londres</li>
</settlement>
</list>
<tree>
<country name="Royaume-Uni">
<region name="Angleterre">
<name sortKey="Quillinan, N" sort="Quillinan, N" uniqKey="Quillinan N" first="N." last="Quillinan">N. Quillinan</name>
</region>
<name sortKey="Denton, C" sort="Denton, C" uniqKey="Denton C" first="C." last="Denton">C. Denton</name>
<name sortKey="Haq, S" sort="Haq, S" uniqKey="Haq S" first="S." last="Haq">S. Haq</name>
<name sortKey="Mcintosh, D" sort="Mcintosh, D" uniqKey="Mcintosh D" first="D." last="Mcintosh">D. Mcintosh</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000636 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000636 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Musique
   |area=    OperaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:2C6A6FB30DD0B4AF084C4EFB9761DEDD51AEC43B
   |texte=   OP0224 A placebo-controlled phase II study of hyperimmune caprine serum as potential treatment for established diffuse cutaneous systemic sclerosis
}}

Wicri

This area was generated with Dilib version V0.6.21.
Data generation: Thu Apr 14 14:59:05 2016. Site generation: Thu Oct 8 06:48:41 2020